Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.

Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, Wang H, Hantel A, Shayne M, Hwang J, Schmotzer A, Ramanathan RK.

Oncology. 2010;78(2):125-9. doi: 10.1159/000312654. Epub 2010 Apr 13.

PMID:
20389134
2.
3.

Docetaxel: in gastric cancer.

Deeks ED, Scott LJ.

Drugs. 2007;67(13):1893-901. Review.

PMID:
17722957
4.

Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel.

Ajani JA.

Expert Opin Pharmacother. 2006 Aug;7(12):1627-31. Review.

PMID:
16872265
5.

Capecitabine: in advanced gastric or oesophagogastric cancer.

Dhillon S, Scott LJ.

Drugs. 2007;67(4):601-10. Review.

PMID:
17352519
6.

Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.

Ma Y, Tang L, Wang HX, Xu YC, Ma Y, Zhang FC.

J Clin Pharm Ther. 2012 Jun;37(3):266-75. doi: 10.1111/j.1365-2710.2011.01289.x. Epub 2011 Sep 26. Review.

PMID:
21950464
7.

Medical treatment for advanced gastroesophageal adenocarcinoma.

Cen P, Ajani JA.

Curr Opin Gastroenterol. 2007 Nov;23(6):631-5. Review. Erratum in: Curr Opin Gastroenterol. 2008 Jan;24(1):101.

PMID:
17906439
8.

Chemotherapy of advanced gastric cancer.

Rivera F, Vega-Villegas ME, López-Brea MF.

Cancer Treat Rev. 2007 Jun;33(4):315-24. Epub 2007 Mar 21. Review.

PMID:
17376598
9.

Capecitabine in gastric cancer.

Bang YJ.

Expert Rev Anticancer Ther. 2011 Dec;11(12):1791-806. doi: 10.1586/era.11.172. Review.

PMID:
22117147
10.

Capecitabine in the treatment of advanced gastric cancer.

Lee JL, Kang YK.

Future Oncol. 2008 Apr;4(2):179-98. doi: 10.2217/14796694.4.2.179. Review.

PMID:
18407732
12.

Docetaxel for gastric and esophageal carcinomas.

Ajani JA.

Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):89-96. Review.

13.

Capecitabine in pretreated metastatic cholangiocarcinoma. A case report and review of the literature.

Koutras AK, Talampuka G, Pagoni N, Thomopoulos KC, Kalliolias G, Kalogeropoulou C, Kalofonos HP.

J BUON. 2007 Apr-Jun;12(2):281-3. Review.

PMID:
17600885
14.

An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.

Haghighat P, Bekaii-Saab T.

J Natl Compr Canc Netw. 2008 Oct;6(9):895-900. Review.

PMID:
18926099
15.

Docetaxel in the treatment of esophageal cancer.

Rigas JR, Dragnev KH, Bubis JA.

Semin Oncol. 2005 Apr;32(2 Suppl 4):S39-51. Review.

PMID:
16015553
16.

The role of capecitabine in the management of tumors of the digestive system.

Gennatas C, Michalaki V, Gennatas S.

Rev Recent Clin Trials. 2009 Jan;4(1):1-11. Review.

PMID:
19149758
17.

Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma.

Bueno Muiño C, Puente Vázquez J, Sastre Valera J, García-Sáenz JA, Martín M, García Miralles N, Sánchez-Pernaute A, Díaz-Rubio E.

Clin Transl Oncol. 2007 May;9(5):335-8. Review.

PMID:
17525046
18.

Capecitabine in the treatment of esophageal and gastric cancers.

Popa EC, Shah MA.

Expert Opin Investig Drugs. 2013 Dec;22(12):1645-57. doi: 10.1517/13543784.2013.842974. Epub 2013 Oct 4. Review.

PMID:
24090307
19.

Docetaxel: its role in current and future treatments for advanced gastric cancer.

Nishiyama M, Wada S.

Gastric Cancer. 2009;12(3):132-41. doi: 10.1007/s10120-009-0521-z. Epub 2009 Nov 5. Review.

PMID:
19890692
20.

Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.

Costa FP, Gumz B, Pasche B.

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):843-54. doi: 10.1016/j.bpg.2012.12.001. Review.

PMID:
23582923

Supplemental Content

Support Center